Acumen reports Q2 2026 results, reaffirms ALTITUDE-AD readout for late 2026
Acumen ended June with $110.2 million in cash and said its Phase 2 sabirnetug trial data are still expected this year, with two new brain-delivery candidates moving toward a 2027 IND.
SEC filing